The FDA's approval of Casgevy — the world's first CRISPR-based gene-editing therapy — in late 2025 marked the beginning of the gene-editing revolution. In the year since, the biotech industry has mobilized billions toward a pipeline of CRISPR-based treatments targeting cancer, cardiovascular disease, Alzheimer's, and hundreds of rare genetic disorders.
The Casgevy approval answered the fundamental question: can gene editing be safely delivered to patients at scale? The answer, based on data from over 200 patients, was a qualified but emphatic yes. Intellia Therapeutics' in vivo therapy for transthyretin amyloidosis demonstrated durable protein reduction in Phase 2 trials. Editas Medicine's therapy for inherited blindness showed vision improvement in 78% of treated eyes.
In oncology, CRISPR engineers patients' immune cells to better attack tumors — a next-gen CAR-T approach — and targets cancer mutations directly. Venture funding for gene-editing reached $8.5 billion in 2026, and Pfizer, Novartis, and Roche have committed over $15 billion to CRISPR partnerships. The ethical framework continues to evolve, distinguishing between somatic editing (broadly accepted) and germline editing (largely prohibited).
/p>Delivery remains the central technical challenge. CRISPR's molecular machinery — the Cas enzyme and guide RNA — must reach the right cells in sufficient quantities to produce a therapeutic effect. For blood disorders like sickle cell disease, the solution has been ex vivo editing: extracting a patient's hematopoietic stem cells, editing them in a laboratory dish, and reinfusing them. This approach works but costs approximately $2.2 million per treatment, limiting access to wealthy healthcare systems. In vivo delivery — editing cells directly inside the patient's body — is the holy grail. Intellia Therapeutics' Phase 2 trial for transthyretin amyloidosis delivered CRISPR via lipid nanoparticles (LNPs) directly into the liver, achieving over 90% reduction in the disease-causing protein with a single intravenous infusion. Expanding this approach to other organs — the brain, the heart, muscle tissue — requires solving organ-specific delivery, one of the hardest problems in drug development.
The pipeline of CRISPR therapeutics now extends far beyond rare diseases. Cancer applications are advancing rapidly: CRISPR-edited CAR-T cells, modified to enhance their tumor-killing ability and resist the immunosuppressive tumor microenvironment, have entered Phase 2 trials for solid tumors including pancreatic cancer and glioblastoma — cancers that have been largely resistant to immunotherapy. Cardiovascular applications target PCSK9, a gene that regulates LDL cholesterol; a single CRISPR edit that permanently lowers PCSK9 expression could replace a lifetime of statin medications, and early human data shows cholesterol reductions of 55-70% sustained beyond two years. For Alzheimer's, researchers are targeting the APOE4 gene variant that increases disease risk, with the goal of converting high-risk APOE4 genotypes to the neutral APOE3 variant.
The ethical and access questions are as pressing as the science itself. At $2.2 million per treatment, Casgevy is out of reach for most patients in most countries; Vertex has established access programs in low-income nations, but the infrastructure required — specialized transplant centers, long-term follow-up care — limits scalability. The World Health Organization has convened a gene-editing governance committee, and the NIH has issued guidelines emphasizing that genetic therapies should address disease, not enhancement. The consensus among bioethicists is that CRISPR should be analogous to other advanced therapies — available based on medical need, not ability to pay — but achieving that ideal in practice will require public investment, price controls, and international coordination on a scale rarely seen outside pandemic response.